# Inositol Mood Meta-analysis: What the Evidence Says
Canonical: https://www.migaku.app/guides/inositol-mood-meta-analysis-evidence-review
Category: evidence-review
Summary: Inositol Mood Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are systematic 
Last reviewed: 2026-08-18
Reviewed by: Migaku Evidence Review
# Inositol Mood Meta-analysis: What the Evidence Says

## Quick Answer

Inositol Mood Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are systematic review, so conclusions should be framed as evidence-aware guidance rather than medical advice.

## Key Takeaways

- This page is generated only from sources stored in the Migaku evidence knowledge base.
- Current evidence mix: 1 systematic review, 1 preclinical study.
- Claims should be interpreted with the source type, study design, population, and publication date in mind.
- This article is educational and does not replace care from a qualified clinician.

## Evidence Map

| Source | Evidence type | Level | Date | Identifier |
| --- | --- | ---: | --- | --- |
| Current Evidence of Acetyl-L-Carnitine Use in Mood Disorders-: A Systematic Review and Meta-Analysis | systematic review | 1 | 2026-06-03 | 10.2147/NDT.S586506 |
| Potential Anxiolytic Effects of Selected Inositol Stereoisomers—A Narrative Review | preclinical study | 4 | 2026-05-24 | 10.3390/cells15110970 |

## What The Sources Report

- In summary, current clinical and preclinical evidence supports the antidepressant properties of acetyl-L-carnitine, particularly in populations with treatment-resistant depression, and cognitive impairment in mood disturbances. [Kumar Rakesh (2026); evidence level 1]
- There is a lack of consistent data and evidence regarding an optimal use of ALC in treatment of depression. [Kumar Rakesh (2026); evidence level 1]
- Anxiety and depressive disorders frequently co-occur, and converging evidence from symptom profiles, longitudinal course, shared neurobiological markers, familial aggregation, and treatment response supports a substantial overlap between these conditions. [Derkaczew Maria (2026); evidence level 4]
- Importantly, even agents considered comparatively "benign", such as non-benzodiazepine anxiolytics, may rarely cause significant neurological adverse effects in vulnerable individuals, as illustrated by reports of buspirone-associated dyskinesia or dystonia, plausibly related to its interactions with dopaminergic signaling. [Derkaczew Maria (2026); evidence level 4]

## How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

## Practical Interpretation

There is at least one systematic-review style source in the current set, so it deserves more weight than single-study evidence. For inositol mood meta-analysis, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

## Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

## References

- Kumar Rakesh (2026). Current Evidence of Acetyl-L-Carnitine Use in Mood Disorders-: A Systematic Review and Meta-Analysis. DOI: 10.2147/NDT.S586506. PMCID: PMC13242760. PMID: 42261369. License: https://creativecommons.org/licenses/by-nc/4.0/ https://www.dovepress.com/terms.php http://creativecommons.org/licens.... https://pmc.ncbi.nlm.nih.gov/articles/PMC13242760/
- Derkaczew Maria (2026). Potential Anxiolytic Effects of Selected Inositol Stereoisomers—A Narrative Review. DOI: 10.3390/cells15110970. PMCID: PMC13256961. PMID: 42274562. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13256961/

## Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.